Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
into a lease agreement (the “Lease Agreement”) with BP
Prucenter Acquisition LLC for the Company’s headquarters located
at 800 Boylston Street, Boston, Massachusetts. The Company’s
current sublease will terminate on August 31, 2017, following
which time the Company will lease the same location from
September 1, 2017 until August 31, 2019 to the terms of the Lease
Agreement. Under the Lease Agreement, the Company will lease
7,234 square feet and the lease payments will be approximately
$38,883 per month.
and is qualified in its entirety by reference to the full text of
the Lease Agreement, a copy of which is filed herewith as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
|
Exhibit No.
|
Description
|
||
|
10.1
|
|
Lease Agreement, dated January 27, 2017, between Flex
Pharma, Inc. and BP Prucenter Acquisition LLC |
About Flex Pharma, Inc. (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs. Flex Pharma, Inc. (NASDAQ:FLKS) Recent Trading Information
Flex Pharma, Inc. (NASDAQ:FLKS) closed its last trading session down -0.24 at 4.02 with 77,524 shares trading hands.